Function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating non-alcoholic fatty liver disease and/or type-2 diabetes

A non-alcoholic, fatty liver disease technology, applied in drug combinations, pharmaceutical formulas, metabolic diseases, etc., can solve problems such as aggravated liver damage, and achieve the effect of improving fatty liver disease

Active Publication Date: 2020-05-26
WUHAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, if type II diabetes is poorly controlled or fully dev...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating non-alcoholic fatty liver disease and/or type-2 diabetes
  • Function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating non-alcoholic fatty liver disease and/or type-2 diabetes
  • Function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating non-alcoholic fatty liver disease and/or type-2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] The present invention will be further elaborated through the following detailed description in conjunction with the accompanying drawings and specific embodiments.

[0026] Experimental animals and feeding:

[0027] Species, gender, age and source of experimental animals: C57BL / 6 (C57) mice and liver-specific Sh3rf2 knockout (Sh3rf2-KO) mice, male, 8 weeks old. C57BL / 6 (WT) mice were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0028] Experimental animal feed formula: high-fat and high-cholesterol feed (HFHC) (purchased from Trophy, product number TP26304), energy composition ratio: protein 14%, fat 42%, carbohydrate 44%, cholesterol 0.2%, 4.5Kcal / g. Low-fat feed (Normal chow, NC) for the control group (purchased from Beijing Huafukang Biotechnology Co., Ltd., item number D12942): energy composition ratio: protein 20%, fat 10%, carbohydrate 70%, 3.85Kcal / g.

[0029] Animal feeding and environmental conditions: All experimental mice were kept in the SPF a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating a non-alcoholic fatty liver disease and/or type-2 diabetes. According to the function and the application, Sh3rf2 gene knockout mice and wild type C57 mice are taken as experiment objects, through a fat mice model induced with high-fat and high-cholesterol (HFHC) diet, it is found that the weight of Sh3rf2 gene knockout mice increases in comparison with that of the wild type C57 mice in a control group; results of the liver weight, the liver/body weight, lipid composition pathological staining and the like all indicate that the Sh3rf2-KO mice in an HFHC group have obviously serious lesion of the fatty liver, and lipid accumulation increases; and the results show that Sh3rf2 gene knockout significantly worsens the progression of the non-alcoholic fatty liver disease. In allusion to the effect of the Sh3rf2, the Sh3rf2 can be used for preparing the drugs for preventing, alleviating and / or treating the nonalcoholic fatty liver disease and/or the type-2 diabetes.

Description

technical field [0001] The invention belongs to the field of gene function and application, and in particular relates to the function and application of (SH3 domain-containingRING finger protein 2, Sh3rf2)Sh3rf2 in the preparation of medicines for treating non-alcoholic fatty liver disease and / or type II diabetes. Background technique [0002] With the increase of aging population, urbanized life and changes in lifestyle, obesity, non-alcoholic fatty liver disease, metabolic syndrome and diabetes and other metabolic abnormalities have increased dramatically, and have now become an important hazard to global public health. [0003] The liver is one of the most important organs of glucose metabolism and the center of substance metabolism. It has many important physiological functions, such as the synthesis and decomposition of glucose, lipid synthesis and decomposition, bile synthesis and secretion, etc. Fatty liver refers to the pathological changes caused by excessive accumu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01K67/027A61K45/00A61P1/16A61P3/10A61P35/00
CPCA01K67/0276A01K67/0278A01K2217/072A01K2217/075A01K2227/105A01K2267/0362A61K45/00A61P1/16A61P3/10A61P35/00
Inventor 李红良折志刚姬燕晓杨霞
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap